MedTrace Logo

A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC

NCT03516071 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2019-09-04

No results posted yet for this study

Summary

This is a Phase 2, Open-label, Randomized, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Brivanib in Patients with Previously Treated Advanced Hepatocellular Carcinoma.

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

DRUG

Brivanib 800 mg, QD

Brivanib Alaninate 800 mg QD, PO

DRUG

Brivanib 400 mg, BID

Brivanib Alaninate 400 mg BID, PO

Sponsors & Collaborators

  • Zai Lab (Shanghai) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-17
Primary Completion
2018-11-09
Completion
2019-07-19

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03516071 on ClinicalTrials.gov